ONCOassist

ONCOassist A revolutionary app designed by oncology professionals for oncology professionals. The go-to app for all oncology professionals.
(1)

It gives them comfort where they can access relevant, up to date tools and content at their fingertips. It is the only mobile-first platform that saves time and improves the quality of patient care for frustrated and under pressure oncology HCPs. With the advent of genomic sequencing, combined with an aging population, and new therapies. The decision-making process for oncology HCP's is becoming increasingly complex. Unfortunately, they have no easy access to the tools and information they need to make an informed decision quickly. This means they use multiple different software and tools to aid their decisions, many of which are not safe and validated. This wastes time & reduces the quality of patient care. We focus on making ONCOassist easily accessible to all oncology HCP’s by being available across multiple devices(iOS, Android, and Desktop) and ensuring safety through CE and FDA compliance. Such is the need for ONCOassist our community of users are actively engaging with us to help define our future tools based on their burning needs. ONCOassist is improving the delivery of cancer care globally and helping us to reach our goal of leveling the standard of care worldwide.

🚨FDA Approval Alert!🔔 FDA grants accelerated approval to Sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.) fo...
21/11/2025

🚨FDA Approval Alert!

🔔 FDA grants accelerated approval to Sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.) for adults with locally advanced or metastatic non-squamous NSCLC harboring HER2 TKD activating mutations after prior systemic therapy.

➡️ FDA also clears the Oncomine Dx Target Test as a companion diagnostic to identify eligible patients.

🔗 Read more: bit.ly/ONCOnews21N-4

🚨FDA Approval Alert!🔔 The FDA has granted full approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen ...
21/11/2025

🚨FDA Approval Alert!

🔔 The FDA has granted full approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech Inc.) in combination with VCd for newly diagnosed light chain (AL) amyloidosis, converting its 2021 accelerated approval to traditional approval.

✅ This decision is supported by results from the ANDROMEDA Phase 3 trial.

🔗 Read more: bit.ly/ONCOnews21N-3

🚨FDA Approval Alert!📢 FDA approves selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromato...
21/11/2025

🚨FDA Approval Alert!

📢 FDA approves selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromatosis type 1 (NF1) experiencing symptomatic, inoperable plexiform neurofibromas.

🔹FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.

🔗 Read more: bit.ly/ONCOnews21N-2

🚨European Union Approval Alert!✅ EU approves Libtayo® (cemiplimab) as the first immunotherapy for adjuvant treatment of ...
21/11/2025

🚨European Union Approval Alert!

✅ EU approves Libtayo® (cemiplimab) as the first immunotherapy for adjuvant treatment of cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation.

📉 Phase 3 C-POST trial: Significant improvement in disease-free survival with a 68% reduction in recurrence.

🔗 Read more: bit.ly/ONCOnews21N-1

🚨FDA Approval Alert!✅ FDA grants full approval to Amgen's IMDELLTRA® (tarlatamab-dlle) in extensive stage small cell lun...
20/11/2025

🚨FDA Approval Alert!

✅ FDA grants full approval to Amgen's IMDELLTRA® (tarlatamab-dlle) in extensive stage small cell lung cancer (ES-SCLC).

🎯 Phase 3 DeLLphi-304 shows 40% reduction in risk of death vs chemo.

🔗 Read more: bit.ly/ONCOnews20N3

🚨Latest in Oncology!🆕 EU approves Roche’s Lunsumio® (mosunetuzumab) subcutaneous (SC) for relapsed/refractory follicular...
20/11/2025

🚨Latest in Oncology!

🆕 EU approves Roche’s Lunsumio® (mosunetuzumab) subcutaneous (SC) for relapsed/refractory follicular lymphoma — offering deep, durable responses even in later-line disease.

⏱️ New subcutaneous option cuts administration time to ~1 minute, supporting faster care and greater treatment flexibility for patients.

🔗 Read more: bit.ly/ONCOnews20N-2

🚨New EC Approval!🔔 The European Commission has approved subcutaneous KEYTRUDA® (pembrolizumab) for all adult EU-approved...
20/11/2025

🚨New EC Approval!

🔔 The European Commission has approved subcutaneous KEYTRUDA® (pembrolizumab) for all adult EU-approved indications — becoming the first and only subcutaneous immune checkpoint inhibitor in Europe.

🔗 Read more: bit.ly/ONCOnews20N-1

🚀 The CTCAE v6 now available in the   app!🔹Stay up to date with the latest adverse event standards.🔹Search and grade adv...
19/11/2025

🚀 The CTCAE v6 now available in the app!

🔹Stay up to date with the latest adverse event standards.
🔹Search and grade adverse events instantly.
🔹Streamline your documentation.
🔹Improve communication and safety in daily oncology practice.

➡️ CTCAE v4 and v5 are still available in the app.

🚨FDA Approval Alert!✅ FDA approves EPKINLY® (epcoritamab-bysp) in combination with Rituximab and Lenalidomide for relaps...
19/11/2025

🚨FDA Approval Alert!

✅ FDA approves EPKINLY® (epcoritamab-bysp) in combination with Rituximab and Lenalidomide for relapsed/refractory follicular lymphoma!

💥 First-ever bispecific antibody combination approved, delivering superior PFS & response rates in Phase 3 EPCORE FL-1 study.

🔗 Read more: bit.ly/ONCOnews19N-1

🚨Latest: Phase III results!📣 Phase 3 results show ZIIHERA® (zanidatamab) delivers strong efficacy as a leading HER2-targ...
18/11/2025

🚨Latest: Phase III results!

📣 Phase 3 results show ZIIHERA® (zanidatamab) delivers strong efficacy as a leading HER2-targeted therapy.

✅ Its combination with TEVIMBRA® (tislelizumab) + chemotherapy is emerging as a new first-line standard of care in HER2-positive gastroesophageal cancer.

✨ First Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy

🔗 Read more: bit.ly/ONCOnews18N-2

🎗️Latest: Major advance in early breast cancer!💊 Roche’s giredestrant becomes the first oral selective oestrogen recepto...
18/11/2025

🎗️Latest: Major advance in early breast cancer!

💊 Roche’s giredestrant becomes the first oral selective oestrogen receptor degrader (SERD) to show superior iDFS vs standard endocrine therapy.

📈 A potential new standard of care emerges - lidERA trial delivers a second Phase III success after evERA trial.

🔗 Read more: bit.ly/ONCOnews18N-1

Address

3rd Floor, 41/42, High Street
Killarney
V93T8K7

Alerts

Be the first to know and let us send you an email when ONCOassist posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ONCOassist:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram